TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Overall cosmetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse outcome (hyperpigmentation)
Endpoint domain: Adverse events/effects
Primary endpoint: Migraine-specific doctor-patient communications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in mean 24-h ambulatory SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mean 24-h ambulatory DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvements in recall memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fewer cognitive complaints
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pathogen eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cone and rod sensitivities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acuity improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma concentration of HIV‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of HSV‐2‐positive genital ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: Mean cumulative morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing severe pain (VAS > 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nonvertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prescription rate of potentially inappropriate medications (PIMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Release of Hg from dental amalgams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Release of Sn after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in microstructure of dental amalgams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discussion and documentation of CIPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate management of mild CIPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Daily Opioid Dose (MEDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPI-SF scores for pain interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPI-SF scores for pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPI-SF scores for worst pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: language ability of children by three years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional performance within the first year of fitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaCO2 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder function score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VocSPL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F2 of the vowel /u/ (F2u)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratio F2i/F2u
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of cardiotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: FBUT measurement reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensation reported with DET strip
Endpoint domain: Adverse events/effects
Primary endpoint: Meconium aspiration syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: buprenorphine bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tolerability of CAM2038 formulations
Endpoint domain: Adverse events/effects
Primary endpoint: average hearing threshold improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective rate of senile sudden deafness patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of combination treatment vs fluoxetine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Likelihood to move away from cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: executive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptom reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in dose of inhaled steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HDM allergen concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: High-density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Serum cholesterol concentration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: uCTX‐II levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year event-free rates of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: 5-year event-free rates of myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: 5-year event-free rates of stroke
Endpoint domain: Mortality/survival
Primary endpoint: wall lesion development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of visual field (VF) deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Children's developmental performance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HVPG response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically free from diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: white cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: NO production by neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: eNOS protein expression in neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: major clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of angiographic restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of change in brain parenchymal fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage rise in PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of ustekinumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exocrine pancreatic function (trypsin content)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endocrine pancreatic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreas size and morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: undetectable serum HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurovascular coupling capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete response rates at 5th day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast-milk intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mental health score (Mental Component Summary)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cefatrizine oral bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summation to action potential amplitude ratio (SP/AP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median daily wear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of training methods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: hospital admission rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: risk of cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean intraocular pressure (IOP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body fat mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selective adverse reactions to diflunisal
Endpoint domain: Adverse events/effects
Primary endpoint: Regression of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preterm, low-birth-weight delivery
Endpoint domain: Mortality/survival
Primary endpoint: Histological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who successfully bypassed the phase I recovery area
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MRSA clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: BMI change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mNIS+7 change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Norfolk QOL-DN score change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: gait speed change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-prescribed opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of abnormal beta(2)-M, Alb and IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recovery of increased serum creatine kinase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Serum Creatinine (SC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Self-motivation levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Capacity to do Guided Exercise Self-help (GES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experience of the indeterminate phase
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Adverse renal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of initial R0 resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ratio of histologically negative margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Risk of high grade prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality-of-life parameters (fatigue)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cumulative incidence of bleeding or spotting episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean scores for hot flushes, sweating episodes and vaginal dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1st event of death from any cause or unplanned hospitalization for cardiovascular reasons
Endpoint domain: Mortality/survival
Primary endpoint: MMP-9 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: full occlusal correction of the malocclusion after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysplasia severity in serrated adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: NPRS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMDQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Development of ascites
Endpoint domain: Adverse events/effects
Primary endpoint: Differential diagnosis of borderline malignancy of gastric tumours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Atonia Index for diagnosis of RBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mid-expiratory flow 25 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Success rate of colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: study drug-related treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Vascular landmark visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Diagnosis of IgE-mediated egg allergy
Endpoint domain: Adverse events/effects
Primary endpoint: Egg-specific IgE levels greater than 0.35 kUA/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Egg-specific IgG4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical cure rates for BI isolates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-stent minimum lumen diameter (MLD) at eight months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from major adverse cardiovascular events (MACE) at 270 days
Endpoint domain: Mortality/survival
Primary endpoint: Global cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: FEV(1)/forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximum bronchodilator response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: asthma control days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom scores for motion sickness
Endpoint domain: Adverse events/effects
Primary endpoint: Average test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cortical silent period lengthening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Iron deficiency prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PPSV vaccination rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCV vaccination rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Solid fusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cage subsidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vertebral fracture rate
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to stable ST-segment recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved stable ST-segment recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Less recurrent ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Performance on CPE pregnancy loss station
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving HIV RNA < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of low-volume treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of AscPEG-2L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain free time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in symptom threshold events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average reduction in symptom interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery from sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of ventilator support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRT response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DASH score at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Level of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net health plan spending
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Out-of-pocket spending by older patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effects of disclosure and collateral information on abuse decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of stinging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean descriptive discomfort score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean linear analogue score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported adherence to PARTICS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timely questionnaire response rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Delay in health seeking for TB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dysfunctional personality features improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in lactose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postanesthetic shivering (PAS) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative pain (visual analog scale scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to return to normal daily life
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Prevalence of M genitalium infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: IGF‐I standard deviation score (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin sensitivity (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lower limb muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: cardio-vascular endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: length growth velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of wound's area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HFMSE score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPT pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance status (PS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative probability of false-positive low-dose CT examinations
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative probability of false-positive chest radiography
Endpoint domain: Adverse events/effects